Efficacy and safety of ginsam, a vinegar extract from Panax ginseng, in type 2 diabetic patients: Results of a double-blind, placebo-controlled study

Journal of Diabetes Investigation

Volumn 3, Issue 3, 2012, Pages 309-317

  Yoon, Ji Won ^a,b   Kang, Seon Mee ^a,c   Vassy, Jason L ^d   Shin, Hayley ^e   Lee, Yun Hee ^c   Ahn, Hwa Young ^a,c   Choi, Sung Hee ^a,c   Park, Kyong Soo ^a   Jang, Hak Chul ^a,c   Lim, Soo ^a,c  

^a Seoul National University   (South Korea)

^b Seoul National University Hospital Healthcare System Gangnam Center   (South Korea)

^c Seoul National University Bundang Hospital   (South Korea)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Ginsam; Oral antidiabetic therapy; Panax ginseng

Indexed keywords

ADIPONECTIN; C REACTIVE PROTEIN; GINSAM; GINSENG EXTRACT; HEMOGLOBIN A1C; INTERLEUKIN 6; LEPTIN; PLACEBO; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VINEGAR;

ADULT; ALCOHOL CONSUMPTION; ARTICLE; BODY MASS; BODY WEIGHT; CONTROLLED STUDY; DIET; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL SYMPTOM; GLUCOSE HOMEOSTASIS; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; MUSCULOSKELETAL PAIN; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SMOKING; UPPER RESPIRATORY TRACT INFECTION; WAIST CIRCUMFERENCE; WEAKNESS;

EID: 84861990728     PISSN: 20401116     EISSN: 20401124     Source Type: Journal    
DOI: 10.1111/j.2040-1124.2011.00185.x     Document Type: Article

References (33)

1. Bahrke MS, Morgan WR. Evaluation of the ergogenic properties of ginseng: an update. Sports Med 2000; 29: 113-133.
2. Dubick MA. Historical perspectives on the use of herbal preparations to promote health. J Nutr 1986; 116: 1348-1354.
3. Vogler BK, Pittler MH, Ernst E. The efficacy of ginseng. A systematic review of randomised clinical trials. Eur J Clin Pharmacol 1999; 55: 567-575.
4. Leung KW, Wong AS. Pharmacology of ginsenosides: a literature review. Chin Med 2010; 5: 1-7.
5. Lu JM, Yao Q, Chen C. Ginseng compounds: an update on their molecular mechanisms and medical applications. Curr Vasc Pharmacol 2009; 7: 293-302.
6. Vuksan V, Sung MK, Sievenpiper JL, et al. Korean red ginseng (Panax ginseng) improves glucose and insulin regulation in well-controlled, type 2 diabetes: results of a randomized, double-blind, placebo-controlled study of efficacy and safety. Nutr Metab Cardiovasc Dis 2008; 18: 46-56.
7. Sotaniemi EA, Haapakoski E, Rautio A. Ginseng therapy in non-insulin-dependent diabetic patients. Diabetes Care 1995; 18: 1373-1375.
8. Yin J, Zhang H, Ye J. Traditional chinese medicine in treatment of metabolic syndrome. Endocr Metab Immune Disord Drug Targets 2008; 8: 99-111.
9. Yun SN, Moon SJ, Ko SK, et al. Wild ginseng prevents the onset of high-fat diet induced hyperglycemia and obesity in ICR mice. Arch Pharm Res 2004; 27: 790-796.
10. Attele AS, Zhou YP, Xie JT, et al. Antidiabetic effects of Panax ginseng berry extract and the identification of an effective component. Diabetes 2002; 51: 1851-1858.
11. Hwang JT, Lee MS, Kim HJ, et al. Antiobesity effect of ginsenoside Rg3 involves the AMPK and PPAR-gamma signal pathways. Phytother Res 2009; 23: 262-266.
12. Kim M, Ahn BY, Lee JS, et al. The ginsenoside Rg3 has a stimulatory effect on insulin signaling in L6 myotubes. Biochem Biophys Res Commun 2009; 389: 70-73.
13. Park MW, Ha J, Chung SH. 20(S)-ginsenoside Rg3 enhances glucose-stimulated insulin secretion and activates AMPK. Biol Pharm Bull 2008; 31: 748-751.
14. Yun SN, Ko SK, Lee KH, et al. Vinegar-processed ginseng radix improves metabolic syndrome induced by a high fat diet in ICR mice. Arch Pharm Res 2007; 30: 587-595.
15. Lim S, Yoon JW, Choi SH, et al. Effect of ginsam, a vinegar extract from Panax ginseng, on body weight and glucose homeostasis in an obese insulin-resistant rat model. Metabolism 2009; 58: 8-15.
16. Vuksan V, Sievenpiper JL, Wong J, et al. American ginseng (Panax quinquefolius L.) attenuates postprandial glycemia in a time-dependent but not dose-dependent manner in healthy individuals. Am J Clin Nutr 2001; 73: 753-758.
17. Yun TK, Choi SY. Non-organ specific cancer prevention of ginseng: a prospective study in Korea. Int J Epidemiol 1998; 27: 359-364.
18. Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-419.
19. Quon MJ. QUICKI is a useful and accurate index of insulin sensitivity. J Clin Endocrinol Metab 2002; 87: 949-951.
20. Xie JT, Aung HH, Wu JA, et al. Effects of American ginseng berry extract on blood glucose levels in ob/ob mice. Am J Chin Med 2002; 30: 187-194.
21. Yang CY, Wang J, Zhao Y, et al. Anti-diabetic effects of Panax notoginseng saponins and its major anti-hyperglycemic components. J Ethnopharmacol 2010; 130: 231-236.
22. Yuan HD, Chung SH. Protective effects of fermented ginseng on streptozotocin-induced pancreatic beta-cell damage through inhibition of NF-kappaB. Int J Mol Med 2010; 25: 53-58.
23. Lai DM, Tu YK, Liu IM, et al. Mediation of beta-endorphin by ginsenoside Rh2 to lower plasma glucose in streptozotocin-induced diabetic rats. Planta Med 2006; 72: 9-13.
24. Yang CY, Xie ZG, Cheng WB, et al. Effects of Panax notoginseng saponins on anti-hyperglycemic, anti-obese and prevention from kidney pathological changes in KK-Ay mice. Zhong Yao Cai 2009; 32: 1571-1576.
25. Reeds DN, Patterson BW, Okunade A, et al. Ginseng and ginsenoside re do not improve {beta}-cell function or insulin sensitivity in overweight and obese subjects with impaired glucose tolerance or diabetes. Diabetes Care 2011; 34: 1071-1076.
26. Bae EA, Han MJ, Choo MK, et al. Metabolism of 20(S)- and 20(R)-ginsenoside Rg3 by human intestinal bacteria and its relation to in vitro biological activities. Biol Pharm Bull 2002; 25: 58-63.
27. Kim K, Park M, Young Kim H. Ginsenoside Rg3 suppresses palmitate-induced apoptosis in MIN6N8 pancreatic beta-cells. J Clin Biochem Nutr 2010; 46: 30-35.
28. Solomon SS, Odunusi O, Carrigan D, et al. TNF-alpha inhibits insulin action in liver and adipose tissue: a model of metabolic syndrome. Horm Metab Res 2010; 42: 115-121.
29. Pradhan AD, Manson JE, Rifai N, et al. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 2001; 286: 327-334.
30. Spranger J, Kroke A, Mohlig M, et al. Inflammatory cytokines and the risk to develop type 2 diabetes: results of the prospective population-based European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study. Diabetes 2003; 52: 812-817.
31. Goldfine AB, Fonseca V, Jablonski KA, et al. The effects of salsalate on glycemic control in patients with type 2 diabetes: a randomized trial. Ann Intern Med 2010; 152: 346-357.
32. Yoon KH, Shin JA, Kwon HS, et al. Comparison of the efficacy of glimepiride, metformin, and rosiglitazone monotherapy in Korean drug-naive type 2 diabetic patients: the practical evidence of antidiabetic monotherapy study. Diabetes Metab J 2011; 35: 26-33.
33. Inzucchi SE. Oral antihyperglycemic therapy for type 2 diabetes: scientific review. JAMA 2002; 287: 360-372.